Supernus Pharmaceuticals (SUPN) Return on Invested Capital (2020 - 2026)
Supernus Pharmaceuticals (SUPN) posted quarterly Return on Invested Capital of 0.02% for Q2 2026, down 3.0% year-over-year from 0.02% in Q2 2025, and down 260.29% on a QoQ basis from 0.01% in Q4 2025.
Supernus Pharmaceuticals (SUPN) Return on Invested Capital (2020 - 2026) Analysis & Trends
Supernus Pharmaceuticals has reported Return on Invested Capital for 7 years, with the latest figure at 0.02% in Q2 2026.
- Return on Invested Capital for Q2 2026 came in at 0.02%, down 3.0% year-over-year; the trailing twelve-month figure through Jun 2026 was 0.02% (down 3.0% YoY), and the FY2025 annual result was 0.01%, down 2.0% from the prior year.
- Return on Invested Capital declined to 0.02% in Q2 2026, from 0.01% in the prior quarter.
- Over five years, Return on Invested Capital peaked at 0.01% in Q1 2022 and troughed at 0.02% in Q2 2026.
- A 5-year average of 0.0% and a median of 0.0% in 2022 frame the typical range for Return on Invested Capital.
- The widest annual swing landed in 2022, when Return on Invested Capital changed 0 bps; it then slipped 3 bps in 2026.
- A 5-year view of Return on Invested Capital shows it stood at 0.0% in 2022, then plunged by 126 bps to 0.0% in 2023, then soared by 2448 bps to 0.0% in 2024, then plunged by 293 bps to 0.01% in 2025, then plunged by 260 bps to 0.02% in 2026.
- Per Business Quant data, the three most recent Return on Invested Capital figures were 0.02% in Q2 2026, 0.01% in Q4 2025, and 0.0% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROIC (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.15 Bn | 39.49 Bn | 2.15 Bn | 0.00% |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.58 Bn | 22.78 Bn | 5.10 Bn | 0.00% |
| 5 | United Therapeutics | 22.16 Bn | 19.50 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | 0.00% |
| 7 | Neurocrine Biosciences | 15.48 Bn | 15.09 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 0.03% |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Supernus Pharmaceuticals | 2.74 Bn | 2.37 Bn | 185.39 Mn | -0.02% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -0.02% |
| Dec 31, 2025 | -0.01% |
| Sep 30, 2025 | 0.00% |
| Jun 30, 2025 | 0.00% |
| Mar 31, 2025 | 0.00% |
| Dec 31, 2024 | 0.00% |
| Sep 30, 2024 | 0.00% |
| Jun 30, 2024 | 0.00% |
| Mar 31, 2024 | 0.00% |
| Dec 31, 2023 | 0.00% |
| Sep 30, 2023 | 0.00% |
| Jun 30, 2023 | 0.00% |
| Mar 31, 2023 | 0.00% |
| Dec 31, 2022 | 0.00% |
| Sep 30, 2022 | 0.00% |
| Jun 30, 2022 | 0.00% |
| Mar 31, 2022 | 0.01% |
| Dec 31, 2021 | 0.01% |
| Sep 30, 2021 | 0.01% |
| Jun 30, 2021 | 0.01% |